B6 Is Not One Molecule Either: Pyridoxine vs P5P, the Neuropathy Signal at High-Dose Pyridoxine, and What the Supplement-Facts Panel Should Say

Pull three B6 supplements off the shelf. The first says "Vitamin B6 (as pyridoxine HCl) 100 mg." The second says "Vitamin B6 (as pyridoxal 5'-phosphate) 25 mg." The third — a B-complex from a mass-market brand — says "Vitamin B6 50 mg" and does not name the form at all. All three are labeled Vitamin B6. Only two of them tell the buyer what molecule is actually in the capsule, and none of the three tells the buyer why the dose was chosen or what dose the body actually needs.

B6 is not a single molecule. It is a family of six closely related vitamers — three alcohols (pyridoxine, pyridoxal, pyridoxamine) and their three 5'-phosphorylated forms (pyridoxine-5'-phosphate, pyridoxal-5'-phosphate, pyridoxamine-5'-phosphate). Of the six, only pyridoxal 5'-phosphate (P5P) is the coenzyme form that actually catalyzes the roughly 150 enzymatic reactions B6 participates in, spanning amino acid metabolism, neurotransmitter synthesis (serotonin, dopamine, GABA, epinephrine), heme synthesis, glycogen metabolism, and the folate-cycle interconversions. Pyridoxine and pyridoxamine — the two forms that show up most often on retail supplement labels — have to be phosphorylated by pyridoxal kinase and then oxidized by pyridoxamine phosphate oxidase before they can serve as coenzymes.

For a healthy adult with a functioning liver and normal pyridoxine kinase activity, that conversion happens routinely. For that person, pyridoxine HCl and P5P at matched doses produce roughly equivalent tissue B6 status, and the "active form" marketing frame is doing more work than the biochemistry supports. But the form question is not the interesting question on a B6 label. The dose question is. Pyridoxine at chronic doses above a few hundred milligrams per day has produced sensory peripheral neuropathy in case reports and case series going back to a 1983 New England Journal of Medicine paper describing seven patients on 2 to 6 grams per day. And regulators in some jurisdictions have moved further down that curve — Australia's Therapeutic Goods Administration now requires a warning label on any supplement containing more than 10 mg of B6 per daily dose, and the UK's Committee on Toxicity of Chemicals in Food set a guidance limit of 10 mg per day of supplemental B6 for the general population in 2023.

This post is the form-and-dose read on B6: what the six vitamers actually are, why the P5P-vs-pyridoxine marketing debate misses the more important question about dose, what the neuropathy literature does and does not support, the specific clinical situations where P5P over pyridoxine is defensible, and the Supplement-Facts patterns that separate a serious B6 product from a mass-market megadose bottle.

The Six Vitamers, and Why P5P Is the One That Matters

The B6 family:

• Pyridoxine (PN) and pyridoxine-5'-phosphate (PNP) — the plant-food form and its phosphorylated derivative. Pyridoxine is the form used in most fortified foods and in the majority of standalone B6 supplements.
• Pyridoxal (PL) and pyridoxal-5'-phosphate (PLP or P5P) — the animal-food form and its phosphorylated coenzyme derivative. P5P is the biochemically active form, the one that binds to B6-dependent enzymes.
• Pyridoxamine (PM) and pyridoxamine-5'-phosphate (PMP) — a third pair, present in animal foods and formed during transamination reactions.

All six interconvert through the enzymes pyridoxal kinase (which adds the phosphate to any of the three alcohols) and pyridoxamine phosphate oxidase (which oxidizes PNP and PMP to PLP). The liver does most of this conversion. Circulating B6 in the plasma is predominantly P5P bound to albumin, and this is the pool that tissues take up.

The functional consequence: a healthy liver takes any oral B6 form, phosphorylates it, oxidizes it if needed, and releases P5P to the bloodstream. For most adults, form choice at matched doses is not the meaningful lever. Dose is.

The Neuropathy Signal at High-Dose Pyridoxine

The B6-neuropathy literature starts with a case series by Herbert Schaumburg and colleagues published in the New England Journal of Medicine in 1983. Seven patients presented with a progressive sensory ataxia — loss of proprioception, unsteady gait, numbness and tingling in the hands and feet — after taking 2 to 6 grams of pyridoxine per day, in most cases for a year or more, on the belief that megadose B6 would help with premenstrual syndrome, carpal tunnel, or general "energy." The neuropathy was a sensory-predominant polyneuropathy affecting the dorsal root ganglia. Symptoms partially resolved after discontinuation but did not fully reverse in every case.

The 1983 paper anchored the recognition that pyridoxine could be neurotoxic at chronic high doses. Subsequent case reports and small case series over the following decades reported neuropathy at doses as low as 100 to 200 mg per day when taken chronically over months to years, though the aggregate picture is less clean than a simple dose threshold — some patients tolerate higher doses for extended periods without symptoms, and reporting bias makes the lower end of the dose curve harder to characterize.

The US Institute of Medicine set the Tolerable Upper Intake Level (UL) for B6 at 100 mg per day from all sources for adults, on the basis of the neuropathy literature. The European Food Safety Authority set the UL at 25 mg per day for adults in a 2023 reassessment. Australia's TGA — as noted above — now requires the neuropathy warning label at doses above 10 mg per day, and the UK COT set a guidance limit at the same 10 mg. These numbers are moving downward as the regulatory reassessments accumulate.

Compare that to the RDA of 1.3 to 1.7 mg per day for adults, and to typical dietary intakes in developed countries of 1.5 to 3 mg per day. A "B6 100 mg" retail supplement is dosing 30 to 60 times the RDA and delivering at or above the US UL from the supplement alone before any food is counted. There is no clinical reason a general-population adult supplementing prophylactically needs 100 mg of B6 per day. The dose exists on the label because the marketing category benchmarked itself against the highest number a competitor put on a bottle two decades ago, not because the biochemistry called for it.

Why the Dose Escalated in the First Place

Three drivers pushed B6 supplement doses into the "100 mg" and "200 mg" tiers that now dominate retail shelves:

Carpal tunnel syndrome and premenstrual syndrome. In the 1970s and 1980s, small trials suggested pyridoxine supplementation might improve carpal-tunnel symptoms and premenstrual mood and fluid retention. The trials were small, the effect sizes modest, and the systematic reviews that followed have not supported a robust effect — but by then the "high-dose B6 for CTS/PMS" pattern had established itself in the supplement category.

"Energy" marketing. B12 and B6 marketing bled into the "adrenal support" and "energy" categories, where higher milligram numbers on the label read as more effective to consumers who assume more is better. Once one brand went to 100 mg, competitors matched.

MTHFR-adjacent marketing. The MTHFR-and-methylation supplement wave that started in the early 2010s pushed "activated" forms of B vitamins — P5P for B6, methylcobalamin for B12, methylfolate for folate — as superior to their "unactivated" counterparts, on the reasoning that people with impaired conversion would benefit from the pre-converted form. The reasoning is defensible for some clinical situations (see below), but the frame overreaches when applied to healthy adults with no conversion defect, and the marketing has tended to conflate the form claim (P5P vs pyridoxine) with the dose claim (whether high-dose B6 is safe or useful at all).

The result is a retail category where "B6" typically means "50 to 100 mg of pyridoxine HCl in a form the label may or may not disclose, at a dose 30-plus times the RDA, on which the regulatory picture has been moving in the direction of tighter limits, not looser."

When P5P Is Actually Indicated Over Pyridoxine

P5P as a distinct supplemental form is defensible in a smaller set of situations than the marketing implies. The situations where the choice matters:

Pyridoxine kinase deficiency and pyridoxamine phosphate oxidase deficiency. These are rare inborn errors of B6 metabolism. Patients with either enzyme defect cannot convert pyridoxine to P5P effectively, and supplemental P5P bypasses the deficient step. These are pediatric-neurology conditions typically managed by specialists, not general-population supplementation.

Advanced liver disease. Because most B6 phosphorylation happens in the liver, patients with cirrhosis or advanced hepatic dysfunction may have reduced capacity to convert pyridoxine to P5P. This is a specialist-managed situation.

Isoniazid therapy for tuberculosis. Isoniazid is a B6 antagonist that binds pyridoxal and P5P and increases urinary loss, and patients on isoniazid are typically co-supplemented with B6 (usually 25 to 50 mg/day of pyridoxine, prescribed by the treating clinician). P5P is not standard here — pyridoxine is the studied form for this indication.

Some seizure syndromes. A subset of pediatric epilepsy syndromes — pyridoxine-dependent epilepsy, pyridoxal-phosphate-dependent epilepsy — respond specifically to one form over another. Again, specialist-managed.

For a healthy adult with no conversion defect, no isoniazid, no advanced liver disease, and no specialist-diagnosed B6-related syndrome, P5P offers no clinically meaningful advantage over pyridoxine at the doses relevant to general supplementation. What actually matters is the total dose delivered, and the total dose most adults need from a supplement — if they need one at all — is in the low single-digit milligrams, not the 25-, 50-, or 100-mg range.

The 20-Second Supplement-Facts Read for B6

A serious B6 product — whether standalone or as part of a B-complex or multivitamin — should let you answer four questions in under 20 seconds by looking at the Supplement Facts panel:

1. What form of B6 is disclosed? The panel should name the form — pyridoxine HCl, pyridoxal 5'-phosphate, or (rarely) pyridoxamine. If the label says only "Vitamin B6" with no form named, that is a transparency failure the buyer should notice.
2. What is the milligram dose per serving, and what percentage of the RDA is that? If the % Daily Value is above a few hundred percent, ask why. A B-complex at 100 to 500% DV is common and generally defensible. A standalone B6 at 5,000 to 10,000% DV is a high-dose product and the buyer should be able to articulate a clinical reason to be at that dose.
3. Is the total dose from all sources — this supplement, other supplements, fortified foods — likely to exceed the applicable regulatory limit? In the US, that is a 100 mg per day UL. In the EU, 25 mg per day. In the UK and Australia, closer to 10 mg per day for chronic use. A person taking a B-complex plus a separate B6 plus a multivitamin can stack past those numbers without noticing.
4. Is there a duration limit implicit in the dose? Short-course, clinically-directed high-dose B6 (for instance, isoniazid co-supplementation) is a different situation from open-ended daily megadose supplementation. If a bottle is dosed at 100 mg with no duration guidance and no clinical indication, the label is inviting a chronic exposure the neuropathy literature does not support.

What a Serious B6 Product Looks Like

The transparency-first read: for general-population supplementation, a B-complex or multivitamin at the RDA-adjacent level of B6 (roughly 1.5 to 5 mg per day of pyridoxine HCl or P5P) is where the biochemistry says the dose should sit. Higher doses belong in specific clinical situations, chosen by a clinician, on a defined duration. Standalone "B6 100 mg" bottles sold to the general population as a shelf-stable product are dosing 20 to 50 times what a healthy adult needs from a supplement, in a category where the regulatory picture is tightening, on a molecule whose chronic-high-dose safety profile has a real signal the marketing category has been reluctant to price in.

The label that gets it right names the form, discloses the dose against the RDA, and does not stack past the regulatory limit for chronic use. The label that gets it wrong hides the form, dose-competes with the shelf, and calls the result "high-potency" without discussing why the potency needs to be that high or how long the buyer is meant to take it. B6 is not a supplement where more is better. It is a supplement where the dose is the question, the form is a secondary question, and the label should answer both without the buyer having to guess.